299 related articles for article (PubMed ID: 25212889)
1. Novel targeted agents in the treatment of multiple myeloma.
Varga C; Laubach J; Hideshima T; Chauhan D; Anderson KC; Richardson PG
Hematol Oncol Clin North Am; 2014 Oct; 28(5):903-25. PubMed ID: 25212889
[TBL] [Abstract][Full Text] [Related]
2. Current and emerging triplet combination therapies for relapsed and refractory multiple myeloma.
Pantani L; Brioli A; Tacchetti P; Zannetti BA; Mancuso K; Rocchi S; Martello M; Rizzello I; Terragna C; Zamagni E; Cavo M
Expert Rev Hematol; 2016 Mar; 9(3):315-23. PubMed ID: 26634945
[TBL] [Abstract][Full Text] [Related]
3. [New drugs in the treatment of multiple myeloma].
Oriol A; Motlló C
Med Clin (Barc); 2014 Sep; 143(6):268-74. PubMed ID: 24342015
[TBL] [Abstract][Full Text] [Related]
4. Emerging biological insights and novel treatment strategies in multiple myeloma.
Gentile M; Recchia AG; Mazzone C; Morabito F
Expert Opin Emerg Drugs; 2012 Sep; 17(3):407-38. PubMed ID: 22920042
[TBL] [Abstract][Full Text] [Related]
5. Contemporary drug therapies for multiple myeloma.
de la Puente P; Azab AK
Drugs Today (Barc); 2013 Sep; 49(9):563-73. PubMed ID: 24086952
[TBL] [Abstract][Full Text] [Related]
6. Future drug developments in multiple myeloma: an overview of novel lenalidomide-based combination therapies.
Morgan G
Blood Rev; 2010 Nov; 24 Suppl 1():S27-32. PubMed ID: 21126634
[TBL] [Abstract][Full Text] [Related]
7. New insights into therapeutic targets in myeloma.
Anderson KC
Hematology Am Soc Hematol Educ Program; 2011; 2011():184-90. PubMed ID: 22160032
[TBL] [Abstract][Full Text] [Related]
8. Targeted therapy of multiple myeloma based upon tumor-microenvironmental interactions.
Anderson KC
Exp Hematol; 2007 Apr; 35(4 Suppl 1):155-62. PubMed ID: 17379101
[TBL] [Abstract][Full Text] [Related]
9. Current strategies for treatment of relapsed/refractory multiple myeloma.
Laubach JP; Voorhees PM; Hassoun H; Jakubowiak A; Lonial S; Richardson PG
Expert Rev Hematol; 2014 Feb; 7(1):97-111. PubMed ID: 24471924
[TBL] [Abstract][Full Text] [Related]
10. Perspectives for combination therapy to overcome drug-resistant multiple myeloma.
Catley L; Tai YT; Chauhan D; Anderson KC
Drug Resist Updat; 2005 Aug; 8(4):205-18. PubMed ID: 16019253
[TBL] [Abstract][Full Text] [Related]
11. Relapsed and refractory multiple myeloma: new therapeutic strategies.
Gentili S; Lonial S
Hematol Oncol Clin North Am; 2014 Oct; 28(5):861-90. PubMed ID: 25212887
[TBL] [Abstract][Full Text] [Related]
12. [Current status of clinical trials of novel agents for multiple myeloma].
Kuroda J
Rinsho Ketsueki; 2014 Oct; 55(10):2005-15. PubMed ID: 25297766
[No Abstract] [Full Text] [Related]
13. Targeting the Immune Niche within the Bone Marrow Microenvironment: The Rise of Immunotherapy in Multiple Myeloma.
Podar K; Jager D
Curr Cancer Drug Targets; 2017; 17(9):782-805. PubMed ID: 28201977
[TBL] [Abstract][Full Text] [Related]
14. The Anti-CD38 Antibody Therapy in Multiple Myeloma.
Petrucci MT; Vozella F
Cells; 2019 Dec; 8(12):. PubMed ID: 31842517
[TBL] [Abstract][Full Text] [Related]
15. Development of targeted therapies for B-cell non-Hodgkin lymphoma and multiple myeloma.
Hernandez-Ilizaliturri FJ; Gowda A; Czuczman MS
Clin Adv Hematol Oncol; 2004 Sep; 2(9):606-18. PubMed ID: 16163245
[TBL] [Abstract][Full Text] [Related]
16. [Novel targeted therapy in multiple myeloma].
Izumi T
Nihon Rinsho; 2014 Jun; 72(6):1089-93. PubMed ID: 25016809
[TBL] [Abstract][Full Text] [Related]
17. Monoclonal antibodies - A new era in the treatment of multiple myeloma.
Jelinek T; Hajek R
Blood Rev; 2016 Mar; 30(2):101-10. PubMed ID: 26362528
[TBL] [Abstract][Full Text] [Related]
18. Histone deacetylase inhibitors in multiple myeloma: rationale and evidence for their use in combination therapy.
Kaufman JL; Fabre C; Lonial S; Richardson PG
Clin Lymphoma Myeloma Leuk; 2013 Aug; 13(4):370-6. PubMed ID: 23787122
[TBL] [Abstract][Full Text] [Related]
19. Elotuzumab as a novel anti-myeloma immunotherapy.
Radhakrishnan SV; Bhardwaj N; Steinbach M; Weidner J; Luetkens T; Atanackovic D
Hum Vaccin Immunother; 2017 Aug; 13(8):1751-1757. PubMed ID: 28604269
[TBL] [Abstract][Full Text] [Related]
20. Limited treatment options in refractory multiple myeloma: promising therapeutic developments.
Oriol A; Abril L; Ibarra G; Senin A
Expert Rev Anticancer Ther; 2020 Jan; 20(1):31-44. PubMed ID: 31865804
[No Abstract] [Full Text] [Related]
[Next] [New Search]